Aralast is an injectable prescription medication indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. Studies show that Aralast augments the concentration of A1-PI in the blood and lungs. Aralast is given once weekly by intravenous infusion. In clinical studies the most common side effects include headache and musculoskeletal discomfort. Your doctor should discuss other rare but potentially serious side effects and potential drug interactions with you prior to treatment.
Click here to view Manufacturers Website